

Neurofibromatosis 1

Neurofibromatosis 1 predisposes affected individuals to the development of benign and malignant tumours that are frequently disfiguring and difficult to manage. However, advances in molecular biology and the development of mouse models have facilitated our understanding of disease pathogenesis. Positron emission tomography has demonstrated that sophisticated imaging techniques have a role in diagnosing complex problems like malignant peripheral nerve sheath tumours, while the prospect of targeted therapies for Nf1 complications is tantalisingly close.

In brief

- Neurofibromatosis 1 is an autosomal-dominant disorder with a prevalence of one in 4000–5000.
- The major diagnostic features are café au lait patches, neurofibromas, skin-fold freckling, iris Lisch nodules, optic pathway glioma and bony dysplasia.
- Neurofibromas are peripheral nerve sheath tumours comprising Schwann cells, fibroblasts, perineurial cells, mast cells, and axons in an extracellular matrix.
- The Schwann cell initiates neurofibroma growth.
- Cognitive impairment is the most common complication and presents with low average IQ, behavioural and specific learning problems.
- There is 10% lifetime risk of developing malignant peripheral nerve sheath tumour (MPNST).
- Symptoms of MPNST are persistent pain, rapid increase in size, change in texture and neurological deficit in association with a neurofibroma.
- Vasculopathy including cardiovascular disease and cerebrovascular disease is a major cause of death in Nf1.
- The gene for Nf1 is on chromosome 17q11.2; the gene product, neurofibromin acts as a tumour suppressor.
- Neurofibromin has multiple functions including negative regulation of $p^{21}RAS$, control of adenylyl cyclase activity and modulation of mTOR (mammalian target of rapamycin.)

Introduction

Neurofibromatosis 1, formerly termed von Recklinghausen's disease, is an autosomal dominant neurocutaneous disorder with a birth incidence of one in 2500 and a minimum prevalence of one in 4–5000.¹ The *Nf1* gene is located on chromosome 17q11.2 and the protein product termed neurofibromin acts as a tumour suppressor.^{2–4} The principal and defining manifestations of Nf1 are *café au lait* patches, neurofibromas (benign peripheral nerve sheath tumours), skin-fold freckling, iris Lisch nodules (hamartomas diagnosed on slit-lamp examination) and character-

istic bony dysplasia of the long bones and sphenoid wing.⁵ The clinical expression and severity in Nf1 is diverse, even within families. The complications affect many of the body systems and range from disfigurement, scoliosis and vasculopathy to cognitive impairment and malignancy including peripheral nerve sheath tumours, and central nervous system gliomas. Macrocephaly, short stature and cutaneous angiomas are minor features of the disease (Figure 1).^{6–9}

Rosalie E Ferner*¹

¹Department of Neurology, Guy's and St Thomas' Hospitals, London, UK

European Journal of Human Genetics (2007) 15, 131–138.
doi:10.1038/sj.ejhg.5201676; published online 6 September 2006

Keywords: neurofibromin; neurofibroma; plexiform neurofibroma; glioma; malignant peripheral nerve sheath tumour

*Correspondence: Dr RE Ferner, Department of Neurology, Guy's and St Thomas' Hospitals, London SE1 9RT, UK.

Tel: +44 020 7188 3970; Fax: +44 020 7848 6123;

E-mail: rosalie.ferner@kcl.ac.uk

Received 22 November 2005; revised 3 May 2006; accepted 4 May 2006;
published online 6 September 2006

Clinical description

The NIH Consensus Development Conference proposed the current clinical diagnostic criteria and nomenclature for neurofibromatosis 1⁵ (Table 1).

Mosaic neurofibromatosis 1

More recently, mosaic forms of neurofibromatosis have been recognised. Somatic mutations arising early in embryogenesis produce generalised disease clinically indistinguishable from nonmosaic Nf1. Localised disease restricted to one part of the body results from later somatic mutations and occurs in one in 36 000 to one in 40 000 individuals.¹⁰




Figure 1 Cutaneous neurofibromas.

Table 1 Diagnostic criteria for neurofibromatosis 1¹

Two or more criteria are needed for diagnosis:

- Six or more *café au lait* patches >15 mm in adults and > 5 mm in children.
- Two or more neurofibromas or one plexiform neurofibroma.
- Axillary or groin freckling.
- Lisch nodules (iris hamartomas).
- Optic pathway glioma.
- A first degree relative with Nf1.
- A distinctive osseous lesion such as sphenoid wing dysplasia or thinning of the long bone cortex with or without pseudoarthrosis.

Diagnosis

The clinical diagnosis of Nf1 is evident by the age of 3 years in the majority of individuals.^{5,6} The presence of UBOs on brain MRI has been advocated as a diagnostic criterion in

young children with one feature of Nf1, but this age group needs general anaesthesia, thereby reducing the usefulness of the investigation. Diagnostic testing is available to confirm the diagnosis in individuals who fulfil the

Table 2 Differential diagnosis of Nf1*Other forms of neurofibromatosis*

1. Segmental/mosaic Nf1.
 2. Neurofibromatosis 2 – bilateral vestibular schwannomas; cranial nerve, spinal, peripheral, cutaneous nerve schwannomas; central nervous system meningiomas, gliomas and juvenile cataracts.
 3. Schwannomatosis (multiple spinal, peripheral nerve and cutaneous schwannomas).
 4. Noonan syndrome – ptosis, hypertelorism, posteriorly rotated ears, slanting palpebral fissures.
 5. Watson phenotype – cognitive impairment, pulmonary stenosis, *café au lait* patches.
 6. Autosomal dominant multiple *café au lait* patches alone.

Conditions with pigment changes confused with Nf1

7. McCune–Albright syndrome – irregular *café au lait* patches, polyostotic fibrous dysplasia.
8. LEOPARD syndrome – multiple lentiginos, ocular hypertelorism, deafness, congenital heart disease.

Overgrowth syndromes

9. Klippel Trenaunay Weber syndrome – cutaneous haemangiomas, varicose veins, hemihypertrophy
10. Proteus syndrome – hyperostoses, hamartomatous overgrowth, epidermal naevi

Conditions causing tumours confused with neurofibromas

11. Multiple lipomas – affect limbs and trunk
12. Bannayan–Riley Ruvalcaba syndrome – multiple lipomas, haemangiomas, macrocephaly pigmented patches on penis
13. Fibromatosis – multiple tumours of muscle, skin, bones and internal organs
14. Multiple endocrine neoplasia type 2B – phaeochromocytomas, mucosal neuromas, medullary carcinoma of thyroid, gastrointestinal ganglioneuromatosis, marfanoid habitus

Mismatch repair syndromes

15. Homozygosity for one of the genes causing hereditary nonpolyposis cancer of the colon

diagnostic criteria for Nf1, but are suspected of having the condition. Current mutation testing permits the identification pathogenic mutations in over 95% of Nf1 patients, using a combination of optimised protein truncation testing, fluorescent *in situ* hybridisation, direct sequencing, Southern blot analysis, and cytogenetic analysis.¹¹ Prenatal testing is possible with foetal DNA extracted from chorionic villous sampling or from amniocentesis. However, requests for prenatal testing are limited because of the inability to predict disease severity. Preimplantation diagnosis may be useful for a couple at risk for having a child with Nf1 and has been introduced in some centres.¹²

- (1) Differential diagnosis.
- (2) The major differential diagnoses of Nf1 are described in Table 2¹³ Clinicians should be aware of individuals with segmental/mosaic Nf1 who present with six or more *café au lait* patches and skin-fold freckling in the affected area. It is important to distinguish between mosaic and generalised Nf1, as the former is a milder condition (see section on Genetic counselling).
- (3) Homozygotes with mismatch repair syndromes can be misdiagnosed as having Nf1 as they have *café au lait* patches and an affected first-degree relative. However, in mismatch repair syndromes the affected relative is a sibling and the parents have a normal phenotype.

Description of disease manifestations

The Skin *Café au lait* patches are present in 95% of Nf1 individuals and usually appear by the age of 3 years. Freckling develops in the majority of children in inter-

**Figure 2** Multiple cutaneous neurofibromas.

triginous areas and hypopigmented macules also occur.⁶ Xanthogranulomas are observed transiently in early childhood in 1–2% of patients as orange papules and have a putative link with juvenile chronic myeloid leukaemia.¹⁴

Neurofibromas and malignant peripheral nerve sheath tumours

Neurofibromas manifest as cutaneous (Figure 2), subcutaneous or plexiform lesions (Figure 3).⁶ Cutaneous neurofibromas cause itching and stinging and subcutaneous lesions often produce pain and neurological deficit from pressure on peripheral nerves.⁶ Neurofibromas rarely develop before age 7 years, usually emerge in late



Figure 3 Benign plexiform neurofibroma of the right leg.

adolescence and frequently increase during pregnancy.^{6,15} The number of tumours differs between individuals and the natural history is uncertain, with periods of rapid growth, followed by phases of quiescence. About 30% of *Nf1* individuals have clinically visible plexiform neurofibromas,⁶ which are frequently congenital, often have a rich vascular supply and involve multiple nerve fascicles. Neurological deficit results from encroachment on surrounding structures and soft tissue and bony hypertrophy may coexist.¹⁶

There is a 7–12% lifetime risk of developing an *Nf1*-associated malignant peripheral nerve sheath tumour (MPNST),¹⁷ which often arises within a pre-existing plexiform neurofibroma and metastases widely, often heralding a poor outcome. Individuals with subcutaneous neuro-



Figure 4 High-grade MPNST on the back.

fibromas are approximately three times more likely to have internal plexiform neurofibromas or MPNSTs than *Nf1* sufferers with no subcutaneous lesions.¹⁸ These individuals warrant increased surveillance for MPNST as well as patients with plexiform neurofibromas in the brachial or lumbosacral plexus, a history of radiotherapy, a personal or family history of malignancy and *Nf1* patients harbouring microdeletions of the *Nf1* gene.⁹ Persistent pain, change in texture, rapid increase in size and neurological deficit associated with a neurofibroma are clinical features of malignancy (Figure 4).⁹ However, MPNSTs are difficult to diagnose, as similar symptoms are encountered in benign neurofibromas, magnetic resonance imaging (MRI) does not reliably distinguish MPNST and blind biopsy might miss the site of malignancy, because the tumours are heterogeneous.⁹

Neurological complications

Cognitive impairment is the most common complication and patients present with low IQ, specific learning problems and behavioural difficulties.⁸ Abnormal executive function, impaired attention and language deficits have been observed. Most patients have an IQ in the low average range around 90 and mental retardation (IQ < 70) is unusual.⁸ There is no evidence that cognitive ability improves with age.⁸

Unidentified bright objects (UBOs) have been identified as focal areas of high signal intensity on T2-weighted MRI.¹⁹ UBOs do not cause overt neurological deficit, they develop in the majority of children with *Nf1*, but most disappear in adulthood.⁸ It has been suggested that they represent delayed myelination or gliosis.²⁰ A link between UBOs and cognitive dysfunction has been postulated, but the association has not been established universally.⁸ Neurological complications originate from malformations like aqueduct stenosis and tumours, including gliomas and

ependymomas.^{6,21} Gliomas occur ubiquitously in the central nervous system, chiefly in the optic pathways, brainstem and cerebellum.^{6,21} Optic pathway gliomas (OPG) are often asymptomatic, but may cause visual impairment, squint, pupillary abnormalities, proptosis and hypothalamic dysfunction.²² They usually occur in the first 6 years of life and older individuals rarely develop symptomatic tumours.²³

Skull and skeletal deformities may entail neurological sequelae – sphenoid wing dysplasia causes the temporal lobe to herniate into the orbit producing pulsating exophthalmos; severe, progressive scoliosis carries the risk of respiratory compromise and spinal cord compression.⁶

Neurofibromas produce neurological symptoms through pressure on peripheral nerves, spinal nerve roots and the spinal cord. Neurofibromatous neuropathy is characterised by a mild distal sensory–motor neuropathy associated with diffuse neurofibromatous change in thickened peripheral nerves.²⁴

Neurofibromatous vasculopathy affects both arterial and venous circulations in the brain and manifestations include cerebral artery stenosis or occlusion, aneurysm and rupture.²⁵ Cerebral haemorrhage accounts for 50% of deaths owing to cerebrovascular disease in Nf1.²⁶ Multiple sclerosis and epilepsy (predominantly complex partial seizures) have been observed in association with Nf1, the latter probably arising from an underlying cortical dysgenesis.^{27,28}

Cardiovascular disease

Cardiovascular disease is a major cause of premature death in patients with Nf1.²⁶ Essential hypertension is common and raised blood pressure owing to renal artery stenosis and phaeochromocytoma are observed. There is a higher than expected frequency of congenital heart disease in Nf1 individuals, particularly of valvular pulmonary stenosis.^{6,25}

Orthopaedic problems

Orthopaedic complications result from intrinsic defects of the skeletal system and from a disruption of bone structure maintenance.²⁹ Bone mineral density is decreased in Nf1 patients, mainly in the load bearing parts. Pseudoarthrosis, a false joint in a long bone, affects 2% of Nf1 patients.⁶ Bowing of the affected long bone, most commonly the tibia, is apparent at birth or in the first few months of life, and fracture develops after trivial injury, with delayed healing. Scoliosis affects 10% of Nf1 patients and may be either idiopathic or dystrophic, the latter, progressive form developing after the age of 6 years, and rarely after the first decade.³⁰

Genetics and molecular biology

Mutations in the *Nf1* gene result in abnormal cell growth and proliferation and the formation of tumours. The *Nf1* gene was identified on chromosome 17q11.2 and encodes

a cytoplasmic protein neurofibromin, which is ubiquitously expressed with high levels of expression in the nervous system.^{2–4} Neurofibromin is related to the guanine triphosphatase-activating proteins and has several known functions. Neurofibromin reduces cell proliferation by promoting the inactivation of *p21^{RAS}*, which has a cardinal role in mitogenic intracellular signalling pathways.³¹ It also binds with microtubules and modulates adenylyl cyclase activity, which plays a cardinal role in cognition (see below).³² A common biochemical pathway for Nf1 and tuberous sclerosis has been identified recently. Neurofibromin regulates mTOR (mammalian target of rapamycin), a serine/threonine kinase that controls cell growth and division.³³ It has been demonstrated that mTOR is activated in *Nf1*-deficient primary cells and Nf1-associated tumours. This activation of mTOR is dependent on ras and P13 kinase, which inactivate the TSC2 gene product tuberin, via AKT. Rapamycin might have a therapeutic role in Nf1 as tumour cell lines derived from patients are sensitive to this mTOR inhibitor.³³

Pathogenesis of neurofibromas

Neurofibromas comprise a mixture of Schwann cells, fibroblasts, perineurial cells, mast cells and axons embedded in an extracellular matrix.³⁴ Schwann cells exhibit loss of *Nf1* expression and the Schwann cell initiates neurofibroma growth. Zhu *et al.*³⁵ ablated *Nf1* function in mouse Schwann cells using a conditional (*cre/lox*) allele and reported a novel observation in a tumour suppressor syndrome. The mice developed neurofibromas identical to those seen in humans, only when null Schwann cells were present on an Nf1 heterozygote background and not in an otherwise normal mouse. They observed increased numbers of mast cells and hypothesised that they might contribute to neurofibroma formation.³⁵ RAS-GTP levels are increased in some neurofibroma Schwann cells but not in fibroblasts, suggesting that other genetic and epigenetic events are required to produce neurofibromas.³⁶ Candidates include expression of epidermal and vascular endothelial growth factors and their receptors and matrix metalloproteinases.^{37,38} Normal cellular relationships within the perineurium are contingent upon closely regulated signalling between Schwann cells, axons, fibroblasts and perineurial cells. Impaired signalling between the components of neurofibromas might promote neurofibroma development.

MPNST

MPNST from Nf1 individuals and sporadic MPNST both exhibit loss of *Nf1* expression.³⁹ However, malignant change demands additional genetic events that inactivate key cell cycle regulators, including p53, p16 and p27-*kip1*.^{40,41} Furthermore, mice with targeted mutations of the *Nf1* and *p53* genes develop MPNST, when these genes are inactivated.⁴²

OPG and astrocytomas

The molecular pathogenesis of OPG has been difficult to unravel because these indolent tumours rarely require surgery. Inactivation of *Nf1* is found in Nf1-associated pilocytic astrocytomas but not in sporadic tumours, in contrast to MPNST. The natural history of OPG formation has been studied in a mouse model with immunohistochemistry and diffusion tensor imaging.⁴³ A 2-month-old mice developed OPG that were demonstrated as contrast enhancing tumours on MRI.⁴³ Microglial cell infiltration and new vessel formation were observed in the period before tumour formation and the OPG exhibited expression of proteins associated with astroglial precursors.⁴³ Recent investigations have shown that loss of neurofibromin in astrocytes leads to the activation of the KRAS isoform in astrocytes and the mTOR–S6 kinase pathway, leading to increased cell proliferation and protein translation.⁴⁴ Rapamycin can block astrocyte proliferation *in vitro*, thereby forming a potential therapeutic target for Nf1-related brain tumours.⁴⁴

Cognition

The adenylyl cyclase pathway has been implicated in deficits in learning and memory in the *Drosophila melanogaster* as the deficits were corrected by protein kinase A activation.³² Studies in mice that are heterozygous for the *Nf1* mutation, suggest that cognitive impairment in Nf1 is linked with excessive RAS activity and increased GABA inhibition in the hippocampus.⁴⁵ Furthermore, the learning problems and the GABA inhibition are reversed by a reduction in RAS, implying that farnesyl transferase inhibitor drugs might play a therapeutic role in cognitive impairment in Nf1.⁴⁵ The cholesterol lowering drug Lovastatin inhibits p21^{RAS}/mitogen activated protein kinase and a recent study demonstrated that the drug reverses learning and attention deficits in a mouse model of Nf1.⁴⁶ Currently, Lovastatin is being investigated as a potential treatment for cognitive impairment in children with Nf1.

Management

Children and adults with Nf1 should be examined yearly by a clinician conversant with Nf1 and its complications. Annual assessment of the skin and blood pressure should be performed in both groups. Children require monitoring of the spine, growth, cognitive development and school progress. Our practice is to perform a visual examination with visual fields, acuity, colour vision developmental maturity allows, and then annual visual assessment is undertaken by the optician.

Neurofibromas

The mainstay of treatment for cutaneous neurofibromas is surgical removal, notwithstanding occasional hypertrophic scarring, and carbon dioxide laser may be indicated for

small, superficial lesions. About 75% of neurofibromas express progesterone receptors, suggesting a potential therapeutic role for antiprogestosterone therapy.⁴⁷ Plexiform neurofibromas are often difficult to remove because of impingement on soft tissue and on major nerves, the tendency of some lesions to bleed profusely and the possibility of re-growth. Radiotherapy is contraindicated because of the risk of malignant transformation. Several chemotherapy trials have been conducted to treat plexiform neurofibromas, including antihistamines, maturation agents, and antiangiogenesis drugs.⁴⁸ A randomised *placebo*-controlled trial is in progress to assess an oral farnesyl-transferase inhibitor and the antifibrotic agent pirfenidone is being evaluated in adults with progressive plexiform and spinal neurofibromas.⁴⁸

MPNST

Clinicians and patients need to be alert to the symptoms of malignant change in a neurofibroma and prompt referral to a specialist NF/sarcoma unit should be ensured.⁹ The use of ¹⁸fluorodeoxyglucose positron emission tomography facilitates early diagnosis of MPNST.⁹ The optimum treatment is surgical excision of the tumour with tumour-free margins.⁹ Radiotherapy improves local control for incompletely excised tumours and for intermediate and high-grade MPNSTs. Chemotherapy with ifosfamide and doxorubicin is palliative in metastatic disease and might play a role in reducing the size of a tumour before surgery.⁹

Orthopaedic problems

Most patients with pseudoarthrosis require surgery and amputation is necessary in severe cases. Recent research suggests that pseudoarthrosis might be treated using autograft mesenchymal stem cells from the healthy iliac crest.⁴⁹ The dystrophic form of scoliosis is characterised by a rapidly progressive curve, requiring early spinal fusion.⁶

OPG

Chemotherapy with vincristine and cisplatin is the optimum treatment for progressive symptomatic OPG, but radiotherapy is not recommended for young children because of neuropsychiatric, endocrinological, and vascular complications.⁵⁰ Screening for asymptomatic OPG is not advocated, as it does not influence the need for treatment or outcome.

Cognitive impairment

Clinicians, teachers and parents should recognise the possibility of educational and behavioural problems in children with Nf1, so that structured remedial teaching can be offered at an early stage.⁸ Children with attention deficit may respond well to dexamphetamine or methylphenidate under skilled supervision.⁸

Genetic counselling

The clinical diagnosis is clearcut in most individuals with Nf1 and where there is doubt the patients should be seen in a specialist clinic before mutation testing is undertaken. Approximately 50% of patients have Nf1 as a new mutation, while an affected parent has a 50% chance of having a child with the disease.⁶

The risk of an individual with mosaic Nf1 passing on generalised disease to an offspring is small but unquantifiable, as it depends on the percentage of body that is affected.¹⁰ Apparently normal parents of an affected child should be examined carefully for the presence of mosaic Nf1. If the parents are normal, the risk of recurrence is probably only barely above the background risk of 1/6000. There is little evidence for the high levels of gonadal mosaicism seen in other conditions such as tuberous sclerosis. As the phenotype of Nf1 is variable, it is difficult to predict the risks of complications in any one individual. A mildly affected patient might have a child with severe disease, and the converse may be true for a parent with severe disease. The chance of an individual with Nf1 having a severely affected child is 8%. Individuals with Nf1 and whole gene deletions have been described and they have distinct phenotype with dysmorphism, significant cognitive impairment and large numbers of cutaneous neurofibromas.⁵¹

There is marked clinical heterogeneity between individuals with Nf1, even within families. Recent research suggests that individuals with *Nf1* microdeletions might be at higher risk of developing MPNST.⁵² This finding has not been universally established and a larger cohort needs to be assessed to verify the premise (Upadhyaya M *et al*, personal communication). It has been hypothesised that the variation in clinical expression in Nf1 is due to the nature, timing or location of 'second hit mutations' at the *Nf1* locus, to somatic mosaicism or to the presence of modifying genes.⁵³ The presence of modifying genes is supported by frequent observations that identical *Nf1* mutations give rise to different clinical phenotypes.

Conclusions

Nf1 is a complex neurocutaneous disease requiring supervision and management by an expert multidisciplinary team. Elucidation of the pathogenesis of Nf1 and advances in treatment will be enhanced by close collaboration between clinicians and scientists and the ready availability of meticulously documented clinical data, blood and tumour tissue for research. The current advances in molecular biology provide the hope of targeted therapy for this distressing disease. However, reliable clinical and radiographic outcome measures must be developed to assess the potential benefits of any future drug trials in patients.

Further Reading

- Friedman JM, Gutmann DH, MacCollin M, Riccardi VM (eds): Neurofibromatosis: Phenotype, Natural History and Pathogenesis. Baltimore, MD: Johns Hopkins University Press, 1999.
- Ward BA, Gutmann DH: Nf1: from Lab bench to Bedside. *Paediatr Neurol* 2005; **32**: 221–228.
- Ducatman B, Scheithauer B, Piepgras D *et al*: Malignant peripheral nerve sheath tumours: a clinicopathological study of 120 cases. *Cancer (Philadelphia)* 1986; **57**: 2006–2021.
- Ferner R, Lucas JD, O'Doherty *et al*: Evaluation of 18-fluorodeoxyglucose positron emission tomography (18FDGPET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. *J Neurol Neurosurg Psychiatr* 2000; **68**: 353–357.
- Xu HM, Gutmann DH: Merlin differentially associates with microtubule and actin cytoskeleton. *J Neurosci Res* 1998; **51**: 403–415.
- Costa RM, Silva AJ: Mouse models of neurofibromatosis type 1: bridging the GAP. *Trends Mol Med* 2003; **9**: 19–23.
- Mautner VF, Kluwe L, Thakker SD *et al*: Treatment of ADHD in neurofibromatosis type 1. *Dev Med Child Neurol* 2002; **44**: 164–170.
- Hyman SL, Shores A, North KN: The nature and frequency of cognitive deficits in children with neurofibromatosis 1. *Neurol* 2005; **11**: 1037–1044.
- Evans DGR, Huson SM, Donnai D *et al*: A clinical study of type 2 neurofibromatosis. *Q J Med* 1992; **84**: 603–618.
- Evans DGR, Baser ME, O'Reilly B *et al*: Management of the patient and family with neurofibromatosis. 2: A consensus conference statement. *Br J Neurosurg* 2005; **19**: 5–12.
- Ramesh V: Merlin and ERM proteins in Schwann cells, neurons and growth cones. *Nat Rev Neurosci* 2004; **5**: 462–470.
- MacCollin M, Chiocca EA, Evans DG *et al*: Diagnostic criteria for schwannomatosis. *Neurology* 2005; **64**: 1838–1845, (Resources, The Children's Tumour Foundation, 95, Pine Street, 16th Floor, New York, NY 10005, USA, E-mail: info@ctf.org, www.ctf.org).

References

- Huson SM, Compston DAS, Clark P *et al*: A genetic study of von Recklinghausen neurofibromatosis in south east Wales. 1. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. *J Med Genet* 1989; **26**: 704–711.
- Viskochil D, Buchberg AN, Xu G *et al*: Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. *Cell* 1990; **62**: 1887–1892.
- Wallace MR, Marchuk DA, Anderson LB *et al*: Type 1 neurofibromatosis gene: identification of a larger transcript disrupted in three NG1 patients. *Science* 1990; **249**: 181–186.
- Xu GF, O'Connell P, Viskochil D *et al*: The neurofibromatosis type 1 gene encodes a protein related to GAP. *Cell* 1990; **62**: 599–608.
- National Institutes of Health Consensus Development Conference Statement: Neurofibromatosis. *Arch Neurol (Chicago)* 1988; **45**: 575–578.
- Huson SM, Harper PS, Compston DAS: Von Recklinghausen neurofibromatosis: clinical and population study in South East Wales. *Brain* 1988; **111**: 55–81.
- Friedman JM, Arbiser J, Epstein JA *et al*: Cardiovascular disease in neurofibromatosis 1: report of the Nf1 cardiovascular task force. *Gen Med* 2002; **4**: 105–111.
- North KN, Riccardi V, Samango-Sprouse C *et al*: Cognitive function and academic performance in neurofibromatosis. 1: Consensus statement from the Nf1 Cognitive Disorders Task Force. *Neurology* 1997; **48**: 1121–1127.
- Ferner RE, Gutmann DH: International consensus statement on malignant peripheral nerve sheath tumours in neurofibromatosis 1. *Cancer Res* 2002; **62**: 1573–1577.
- Ruggieri M, Huson SM: The clinical and diagnostic implications of mosaicism in the neurofibromatoses. *J Neurol* 2001; **56**: 1433–1443.

- 11 Messiaen LM, Callens T, Mortier G *et al*: Exhaustive mutation analysis of the Nf1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. *Hum Mutat* 2000; **15**: 541–555.
- 12 Verlinsky Y, Rechitsky S, Verlinsky O *et al*: Preimplantation diagnosis for neurofibromatosis. *Reprod Biomed Online* 2002; **4**: 218–222.
- 13 Viskochil D, Carey JC: Alternate and related forms of the neurofibromatoses; in Huson SM, Hughes RACH (eds): *The Neurofibromatoses*. London: Chapman & Hall, pp 445–474.
- 14 Zvulunov A, Bark Y, Mejer A: Juvenile xanthogranulomas, neurofibromatosis and juvenile chronic myelogenous leukaemia. World statistical analysis. *Arch Dermatol* 1995; **131**: 904–908.
- 15 Dugoff L, Sujansky E: Neurofibromatosis type 1 and pregnancy. *Am J Med Genet* 1996; **66**: 7–10.
- 16 Korf B, Huson SM, Needle M *et al*: Report of the working group on neurofibroma. *Nat Neurofibromatosis Found Inc* 1997; 4–27.
- 17 Evans DG, Baser ME, McGaughan J *et al*: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet* 2002; **39**: 311–314.
- 18 Tucker T, Wolkenstein P, Revuz J *et al*: Association between benign and malignant peripheral nerve sheath tumours in Nf1. *Neurol* 2005; **65**: 205–211.
- 19 Bognanno JR, Edwards MK, Lee TA *et al*: Cranial MR imaging in neurofibromatosis. *Am J Radiol* 1988; **151**: 381–388.
- 20 DiPaolo DP, Zimmerman RA, Rorke LB *et al*: Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. *Radiology* 1995; **195**: 721–724.
- 21 Créange A, Zeller J, Rostaing-Rigattieri S *et al*: Neurological complications of neurofibromatosis type 1 in adulthood. *Brain* 1999; **122**: 473–481.
- 22 Listerneck R, Louis DN, Packer RJ *et al*: Optic pathway gliomas in children with neurofibromatosis type 1: Consensus statement from the Nf1 optic pathway glioma study. *J Paediatr* 1994; **125**: 63–66.
- 23 Listerneck R, Ferner RE, Piersall L *et al*: Late-onset optic pathway tumours in children with neurofibromatosis 1. *Neurology* 2004; **63**: 1944–1946.
- 24 Ferner RE, Hall SM, Hughes RAC *et al*: Neurofibromatous neuropathy in neurofibromatosis 1. *J Med Genet* 2004; **41**: 837–841.
- 25 Friedman JM, Arbiser J, Epstein JA *et al*: Cardiovascular disease in neurofibromatosis. 1: A report of the Nf1 Cardiovascular Task Force. *Genet Med* 2003; **4**: 105–111.
- 26 Rasmussen SA, Yang Q, Friedman JM: Mortality in neurofibromatosis. 1: An analysis using US death certificates. *Am J Hum Genet* 2001; **68**: 1110–1118.
- 27 Ferner RE, Hughes RAC, Johnson MR: Neurofibromatosis 1 and multiple sclerosis. *J Neurol Neurosurg Psychiatr* 1995; **56**: 492–495.
- 28 Vivarelli R, Grosso S, Calabrese F *et al*: Epilepsy in neurofibromatosis 1. *J Child Neurol* 2003; **18**: 338–342.
- 29 Kuorilehto T, Poyhonen M, Bloigu R *et al*: Decreased bone mineral density and content in neurofibromatosis type 1: Lowest local values are located in the load-carrying parts of the body. *Osteoporosis Int* 2005; **16**: 928–936.
- 30 Crawford Jr AH, Bagamery N: Osseous manifestations of neurofibromatosis in childhood. *J Pediatr Orthop* 1986; **6**: 72–88.
- 31 Gutmann DH, Wood DL, Collins FS: Identification of the neurofibromatosis 1 gene product. *Proc Natl Acad Sci USA* 1991; **88**: 9658–9762.
- 32 Guo HF, Tong J, Hannan F *et al*: A neurofibromatosis -1- regulated pathway is required for learning in *Drosophila*. *Nature* 2000; **403**: 895–898.
- 33 Johannessen CM, Reczek EE, James MF *et al*: The Nf1 tumour suppressor critically regulates TSC2 and m TOR. *Proc Natl Acad Sci USA* 2005; **102**: 8573–8578.
- 34 Kimura M, Kamata Y, Matsumoto K *et al*: Electron microscopical study on the tumour of von Recklinghausen's neurofibromatosis. *Pathol Jpn* 1974; **24**: 79–91.
- 35 Zhu Y, Ghosh P, Charnay P *et al*: Neurofibromas in Nf1: Schwann cell origin and role of tumour environment. *Science* 2002; **296**: 920–922.
- 36 Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N: Single cell RAS-GTP analysis reveals altered RAS activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. *J Biol Chem* 2000; **275**: 30740–30745.
- 37 DeClue JE, Heffelfinger S, Benvenuto G *et al*: Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumours and Nf1 animal models. *J Clin Invest* 2000; **105**: 1233–1241.
- 38 Muir D: Differences in proliferation and invasion by normal, transformed and Nf1 Schwann cell cultures are influenced by matrix metalloproteinase expression. *Clin Exp Metast* 1995; **13**: 303–314.
- 39 Guha A, Lau N, Huvar I *et al*: RAS-GTP levels are elevated in human peripheral nerve tumours. *Oncogene* 1996; **12**: 507–513.
- 40 Nielsen GP, Stemmer-Rachamimov AO, Ino Y *et al*: Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKNA/p16 inactivation. *Am J Pathol* 1999; **155**: 1879–1884.
- 41 Kourea HP, Cordon-Cardo C, Dudas M *et al*: The emerging role of p27^{kip} in malignant transformation of neurofibromas. *Am J Pathol* 1999; **155**: 1885–1891.
- 42 Cichowski K, Shih TS, Schmitt E *et al*: Mouse models of tumour development in neurofibromatosis type 1. *Science (Washington, DC)* 1999; **286**: 2172–2176.
- 43 Bajenaru ML, Garbow JR, Perry A *et al*: Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. *Ann Neurol* 2005; **57**: 119–127.
- 44 Dasgupta B, Yi Y, Chen DY *et al*: Proteomic analysis reveals hyper-activation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumours. *Cancer Res* 2005; **1**: 2755–2760.
- 45 Costa RM, Federov NB, Kogan JH *et al*: Mechanisms for the learning deficits in a mouse model of neurofibromatosis 1. *Nature* 2002; **415**: 526–530.
- 46 Li W, Kushner SA, Brown RA *et al*: The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis 1. *Curr Biol* 2005; **15**: 1961–1967.
- 47 McLaughlin ME, Jacks T: Progesterone receptor expression in neurofibromas. *Cancer Res* 2003; **63**: 752–755.
- 48 Packer RJ, Gutmann DH, Rubenstein A *et al*: Plexiform neurofibromas in N1: toward biologic-based therapy. *Neurology* 2002; **58**: 1461–1470.
- 49 Kitoh H, Kitakoji T, Tsuchiya H *et al*: Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis – a preliminary result of three cases. *Bone* 2004; **35**: 892–898.
- 50 Packer RJ, Alter J, Allen J *et al*: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. *J Neurosurg* 1997; **86**: 747–754.
- 51 Tonsgard JH, Yelavarthi KK, Cushner S *et al*: Do Nf1 gene deletions result in a characteristic phenotype? *Am J Med Genet* 1997; **73**: 80–86.
- 52 De Raedt T, Brems H, Wolkenstein P *et al*: Elevated risk for MPNST in Nf1 microdeletion patients. *Am J Hum Genet* 2003; **72**: 1288–1292.
- 53 Easton DF, Ponder MA, Huson SM *et al*: An analysis of variation in expression of neurofibromatosis type 1 (Nf1): evidence for modifying genes. *Am J Hum Genet* 1993; **53**: 305–313.